

# INSTITUTIONAL RESEARCH

## *Healthcare and Technology*

### MORNING NOTE

April 25, 2013

#### **Arrowhead Research (Nasdaq/ARWR/Buy/\$1.69)**

#### **NeuroMetrix (Nasdaq/NURO/Buy/\$2.12)**

**Robert M. Wasserman**

Director of Research

561-208-2905

[russwasserman@dawsonjames.com](mailto:russwasserman@dawsonjames.com)

**1) Arrowhead Research (Nasdaq/ARWR/Buy/\$1.69)** – Arrowhead Research will be presenting at two investor conferences in the near future:

- Master Investor, the UK's leading investment show, on Saturday, April 27 at 2:05 p.m. BST at the Business Design Centre in London. Dr. Chris Anzalone, Arrowhead's CEO will be presenting. Details can be found on the event website at <http://masterinvestor.co.uk/>; and
- The Needham Healthcare Conference on Tuesday, April 30 at 8:40 a.m. Eastern time at the Westin Grand Central Hotel in New York City. Dr. Bruce Given, the Company's COO and Head of R&D will be making the presentation. A live webcast of the presentation can be accessed by visiting the News & Events section of Arrowhead's website, <http://www.arrowheadresearch.com/presentations>. A replay will also be archived on the website and available for 60 days.

We currently rate ARWR shares a Buy with a \$4.00 price target. **RMW**

**2) NeuroMetrix (Nasdaq/NURO/\$2.12)** – NeuroMetrix reported financial results for their Q1/2013 this morning and will hold a conference call at 8 am. Results included revenues of \$1.4 million, down from \$2.1 million in Q1/12, but Q1/13 revenues included \$348,000 in sales from new diabetes-related products with the balance of \$1.05 million in revenue derived from the legacy business. Gross profit improved during the quarter to 59% from 46% in the year earlier period, while NeuroMetrix was able to reduce operating costs to \$3.1 million this year, down from \$3.7 million last year. Net loss for the quarter was \$2.3 million or \$1.06 per share, an improvement from the net loss of \$2.8 million or \$1.99 per share in Q1/2012. Operating cash burn was \$1.8 million for the Company in the first quarter, and at the end of March NeuroMetrix had \$6.9 million in cash on hand. The Company reported several advancements related to the recent launch of its SENSUS device for pain management during the first quarter, including initial shipment of 145 devices and filing of a 510(k) for expanded indications relating to use of SENSUS during sleep. NeuroMetrix also announced yesterday the signing of a sales distribution agreement for its DPNCheck device with Omron Healthcare in Japan and earlier in the quarter had signed a similar agreement with Handok Pharmaceuticals for the South Korean market. We currently rate NURO shares a Buy with a \$6.30 price target. **RMW**

Morning Notes provide current information we believe might be noteworthy to investors regarding the subject companies. Morning Notes are not intended to be complete research reports. More detailed information concerning the rated companies referenced in this Note, including the full reports, basis for price targets and other disclosures, may be found at:  
<http://www.DawsonJames.com/portal.html>

**Important Disclosures:**

Dawson James Securities, Inc. (the "Firm") is a member of the Financial Industry Regulatory Authority ("FINRA") and the Securities Investor Protection Corporation ("SIPC").

The Firm does not make a market in the securities of the profiled companies. The Firm has received investment banking compensation from the companies (ARWR and NURO) profiled in this report and may seek compensation for investment banking services in the future. The Firm has not received any other compensation from the profiled companies in the last 12 months.

Neither the research analyst(s) whose name appears on this report nor any member of his (their) household is an officer, director or advisory board member of these companies. The Firm and/or its directors and employees may own securities of the company(s) in this report and may increase or decrease holdings in the future. As of March 31, 2013, the firm as a whole did not own 1% or more of any class of common equity securities of the subject companies.

The Firm, its officers, directors, analysts or employees may effect transactions in and have long or short positions in the securities (or options or warrants related to those securities) of the companies subject to this report. The Firm may effect transactions as principal or agent in those securities.

Analysts receive no direct compensation in connection with the Firm's investment banking business. All Firm employees, including the analyst(s) responsible for preparing this report, may be eligible to receive non-product or service specific monetary bonus compensation that is based upon various factors, including total revenues of the Firm and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report.

Although the statements in this report have been obtained from and are based upon recognized statistical services, issuer reports or communications, or other sources that the Firm believes to be reliable, we cannot guarantee their accuracy. All opinions and estimates included in this report constitute the analyst's judgment as of the date of this report and are subject to change without notice.

The securities of the company discussed in this report may be unsuitable for investors depending on their specific investment objectives and financial position. This report is offered for informational purposes only, and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such would be prohibited. Additional information is available upon request.

**Ratings Definitions:**

- 1) **Buy:** the analyst believes the price of the stock will appreciate and produce a total return of at least 20% over the next 12-18 months;
- 2) **Neutral:** the analyst believes the price of the stock is fairly valued for the next 12-18 months;
- 3) **Sell:** the analyst believes the price of the stock will decline by at least 20% over the next 12-18 months and should be sold.

The following chart reflects the range of current research report ratings for all companies followed by the analysts of the Firm. The chart also reflects the research report ratings relating to those companies for which the Firm has performed investment banking services.

<b>Ratings Distribution</b>	<b>Company Coverage</b>		<b>Investment Banking</b>	
	# of Companies	% of Total	# of Companies	% of Totals
Market Outperform (Buy)	13	81%	8	62%
Market Perform (Neutral)	3	19%	1	33%
Market Underperform (Sell)	0	0%	0	0%
Total	16	100%	9	56%

### **Analyst Certification:**

The analyst(s) whose name appears on this research report certifies that 1) all of the views expressed in this report accurately reflect his (their) personal views about any and all of the subject securities or issuers discussed; and 2) no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst in this research report; and 3) all Dawson James employees, including the analyst(s) responsible for preparing this research report, may be eligible to receive non-product or service specific monetary bonus compensation that is based upon various factors, including total revenues of Dawson James and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report.